EMA Authorised: Clopidogrel Taw Pharma (previously Clopidogrel Mylan) (clopidogrel hydrochloride) — Taw Pharma (Ireland) Limited

View source ↗

Summary

EMA authorised a clopidogrel product (clopidogrel hydrochloride) by Taw Pharma (Ireland) Limited for peripheral vascular diseases, stroke, myocardial infarction…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome
• Myocardial Infarction
• Peripheral Vascular Diseases
• Stroke

Drugs mentioned

• Clopidogrel Taw Pharma (clopidogrel hydrochloride)

Snippet

Status: Authorised. Therapeutic area: Peripheral Vascular Diseases;Stroke;Myocardial Infarction;Acute Coronary Syndrome. MAH: Taw Pharma (Ireland) Limited. Decision date: 18/12/2023